Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Shanghai Henlius Biotech, Inc. Class H ( (HK:2696) ) has issued an update.
Shanghai Henlius Biotech, Inc. announced the dosing of the first patient in a Phase 1/3 clinical study of its Ipilimumab biosimilar, HLX13, for the treatment of unresectable advanced hepatocellular carcinoma in mainland China. This trial aims to assess the pharmacokinetic profiles, efficacy, safety, and immunogenicity of HLX13 compared to its reference product, YERVOY. The study’s successful progression could enhance the company’s market position in the oncology biosimilar sector, potentially impacting stakeholders positively by expanding treatment options for various cancers.
More about Shanghai Henlius Biotech, Inc. Class H
Shanghai Henlius Biotech, Inc. operates in the biotechnology industry, focusing on the development of biosimilar and innovative monoclonal antibodies. The company targets various cancers including melanoma, renal cell carcinoma, colorectal cancer, hepatocellular carcinoma, non-small cell lung cancer, malignant pleural mesothelioma, and esophageal squamous cell cancer. It has entered into a license agreement with Sandoz AG for the commercialization of its products in several major markets.
Average Trading Volume: 1,585,079
Technical Sentiment Signal: Buy
Current Market Cap: HK$20.6B
See more data about 2696 stock on TipRanks’ Stock Analysis page.